Aspira Women's Health Faces Nasdaq Delisting Warning
Ticker: AWHL · Form: 8-K · Filed: Oct 18, 2024 · CIK: 926617
| Field | Detail |
|---|---|
| Company | Aspira Women'S Health INC. (AWHL) |
| Form Type | 8-K |
| Filed Date | Oct 18, 2024 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $1.00, $1.00 m |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, nasdaq
Related Tickers: ASPW
TL;DR
Nasdaq's kicking Aspira out, they're fighting back.
AI Summary
Aspira Women's Health Inc. received a notice on October 17, 2024, indicating it failed to meet a continued listing rule or standard for the Nasdaq Capital Market. The company is currently evaluating the notice and its options, which may include appealing the determination.
Why It Matters
This filing signals potential delisting from the Nasdaq, which could significantly impact the company's liquidity, investor confidence, and ability to raise capital.
Risk Assessment
Risk Level: high — Failure to meet listing standards and potential delisting poses a significant threat to the company's operations and market presence.
Key Players & Entities
- Aspira Women's Health Inc. (company) — Registrant
- Nasdaq Capital Market (company) — Exchange where listing is at risk
- October 17, 2024 (date) — Date of notice
FAQ
What specific listing rule did Aspira Women's Health Inc. fail to meet?
The filing states that the company received a notice regarding failure to satisfy a continued listing rule or standard for the Nasdaq Capital Market, but does not specify the exact rule.
What are the company's immediate next steps after receiving this notice?
Aspira Women's Health Inc. is currently evaluating the notice and its options, which may include appealing the determination.
When did the company receive this notice?
The company received the notice on October 17, 2024.
What is the potential consequence of failing to meet Nasdaq's listing standards?
The potential consequence is delisting from the Nasdaq Capital Market.
Has the company previously been known by other names?
Yes, the company was formerly known as VERMILLION, INC., CIPHERGEN BIOSYSTEMS INC, and ABIOTIC SYSTEMS.
Filing Stats: 684 words · 3 min read · ~2 pages · Grade level 12.9 · Accepted 2024-10-18 16:00:39
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share AWH Nasdaq Capital Marke
- $1.00 — ness days, had closed below the minimum $1.00 per share and, as a result, the Company
- $1.00 m — e Company is not in compliance with the $1.00 minimum bid price requirement for the con
Filing Documents
- form8-k.htm (8-K) — 38KB
- 0001493152-24-041561.txt ( ) — 211KB
- awh-20241017.xsd (EX-101.SCH) — 3KB
- awh-20241017_lab.xml (EX-101.LAB) — 33KB
- awh-20241017_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ASPIRA WOMEN'S HEALTH INC. Date: October 18, 2024 By: /s/ Nicole Sandford Nicole Sandford Chief Executive Officer -3-